PARP Inhibitors in First-Line Therapy of Ovarian Cancer: Are There Any Doubts?

by Franzese, Elisena, Diana, Anna, Centonze, Sara, Pignata, Sandro, De Vita, Ferdinando, Ciardiello, Fortunato, Orditura, Michele
Published in Front Oncol (2020)

Early Triple Negative Breast Cancer: Conventional Treatment and Emerging Therapeutic Landscapes

by Diana, Anna, Carlino, Francesca, Franzese, Elisena, Oikonomidou, Olga, Criscitiello, Carmen, De Vita, Ferdinando, Ciardiello, Fortunato, Orditura, Michele
Published in Cancers (Basel) (2020)

Comparison of the current AJCC-TNM numeric-based with a new anatomical location-based lymph node staging system for gastric cancer: A western experience

by Galizia, Gennaro, Lieto, Eva, Auricchio, Annamaria, Cardella, Francesca, Mabilia, Andrea, Diana, Anna, Castellano, Paolo, De Vita, Ferdinando, Orditura, Michele
Published in PLoS One (2017)

Genomic Profile and BRCA-1 Promoter Methylation Status in BRCA Mutated Ovarian Cancer: New Insights in Predictive Biomarkers of Olaparib Response

by Franzese, Elisena, Centonze, Sara, Diana, Anna, Lombardi, Angela, Carlino, Francesca, Guerrera, Luigi Pio, De Vita, Ferdinando, Caraglia, Michele, Pignata, Sandro, Ciardiello, Fortunato, Orditura, Michele
Published in Front Oncol (2019)

Exemestane and Everolimus combination treatment of hormone receptor positive, HER2 negative metastatic breast cancer: A retrospective study of 9 cancer centers in the Campania Regi...

by Riccardi, Ferdinando, Colantuoni, Giuseppe, Diana, Anna, Mocerino, Carmela, Cartenì, Giacomo, Lauria, Rossella, Febbraro, Antonio, Nuzzo, Francesco, Addeo, Raffaele, Marano, Ombretta, Incoronato, Pasquale, De Placido, Sabino, Ciardiello, Fortunato, Orditura, Michele
Published in Mol Clin Oncol (2018)

NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice

by De Vita, Ferdinando, Ventriglia, Jole, Febbraro, Antonio, Laterza, Maria Maddalena, Fabozzi, Alessio, Savastano, Beatrice, Petrillo, Angelica, Diana, Anna, Giordano, Guido, Troiani, Teresa, Conzo, Giovanni, Galizia, Gennaro, Ciardiello, Fortunato, Orditura, Michele
Published in BMC Cancer (2016)

Phosphatidylinositol 3-kinase (PI3Kα)/AKT axis blockade with taselisib or ipatasertib enhances the efficacy of anti-microtubule drugs in human breast cancer cells

by Morgillo, Floriana, Della Corte, Carminia Maria, Diana, Anna, Mauro, Concetta di, Ciaramella, Vincenza, Barra, Giusi, Belli, Valentina, Franzese, Elisena, Bianco, Roberto, Maiello, Evaristo, de Vita, Ferdinando, Ciardiello, Fortunato, Orditura, Michele
Published in Oncotarget (2017)

Neutrophil to lymphocyte ratio (NLR) for prediction of distant metastasis-free survival (DMFS) in early breast cancer: a propensity score-matched analysis

by Orditura, Michele, Galizia, Gennaro, Diana, Anna, Saccone, Ciro, Cobellis, Luigi, Ventriglia, Jole, Iovino, Francesco, Romano, Ciro, Morgillo, Floriana, Mosca, Lavinia, Diadema, Maria Rosaria, Lieto, Eva, Procaccini, Eugenio, De Vita, Ferdinando, Ciardiello, Fortunato
Published in ESMO Open (2016)

Eribulin for metastatic breast cancer (MBC) treatment: a retrospective, multicenter study based in Campania, south Italy (Eri-001 trial)

by Orditura, Michele, Gravina, Adriano, Riccardi, Ferdinando, Diana, Anna, Mocerino, Carmela, Leopaldi, Luigi, Fabozzi, Alessio, Giordano, Guido, Nettuno, Raffaele, Incoronato, Pasquale, Barzelloni, Maria Luisa, Caputo, Roberta, Pisano, Agata, Grimaldi, Giuseppe, Genua, Geppino, Montesarchio, Vincenzo, Barbato, Enrico, Iodice, Giovanni, Lieto, Eva, Procaccini, Eugenio, Mabilia, Roberto, Febbraro, Antonio, Laurentiis, Michelino De, Ciardiello, Fortunato
Published in ESMO Open (2017)